Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. News
    3. Search results
    Displaying results 76 - 100 of 624 Clear search
    Zyme Communications
    Vortex Biotech
    Healthcare and Life Science 27 Jan 2026

    Vortex Biotech opens new state-of-the-art laboratory at Manchester Science Park

    Expansion accelerates the development of its non-invasive cancer diagnostic solutions 

    Zyme Communications
    ProImmune
    Healthcare and Life Science 21 Jan 2026

    ProImmune introduces Mastering Immunity 2026 - Shanghai Symposium to address key immunogenicity challenges

    Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape Speakers include thought leaders in biotherapeutics, complex peptide drug developers, and regulatory authoritiesIn-
    Zyme Communications
    Rob Walton, CEO, SPT Labtech
    Healthcare and Life Science 14 Jan 2026

    SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT’s firefly platform

    Automated Twist NGS library preparation workflows available on SPT Labtech’s firefly platform via the firefly cloud Validated methods support Twist FlexPrep™ UHT and Enzymatic Fragmentation Kit 2.0, enabling higher throughput and reproducibility in NGS library preparati
    Zyme Communications
    https://axolbio.com/
    Healthcare and Life Science, Science and Engineering 13 Jan 2026

    Axol Bioscience raises $2.8M to advance US expansion and product development

    Financing led by US life sciences investor, BroadOak Capital Partners Investment to support expansion of US operations, product development, and cell manufacturing scale-up

    Cambridge / Edinburgh, UK, 13th January 2026: Axol B

    Zyme Communications
    Dr Nathan Brown, Director of Science at Optibrium
    Healthcare and Life Science 13 Jan 2026

    Optibrium appoints Dr Nathan Brown as Director of Science

    Newly created role underscores commitment to customer-driven research and scientific excellence

    Zyme Communications
    OutSee’s leadership team – James Peach (Left), COO, Dr Julian Gough (Centre), CEO and Founder, and Dr Chang Lu (Right), CSO
    Healthcare and Life Science 12 Jan 2026

    OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

    Oversubscribed £2.5M seed round led by Ahren Innovation CapitalStrategic collaboration with o2h to progress drug discovery programme

    Cambridge, UK, 12 January 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-ba

    Zyme Communications
    Steve Smith, CEO, iXCells Biotechnologies
    Healthcare and Life Science 12 Jan 2026

    iXCells Biotechnologies appoints Steve Smith as CEO

    Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services

    Zyme Communications
    FairJourney Bio
    Healthcare and Life Science 12 Jan 2026

    FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

    Expanded offering provides high-resolution structural insights to support antibody discovery and biologic design

    Zyme Communications
    Rebecca Simmons, PhD, COO, Qureight
    Healthcare and Life Science 12 Jan 2026

    Qureight appoints Rebecca Simmons as Chief Operating Officer

    Experienced operational leader across medical research and deep tech appointed to support sustainable growth as part of Qureight’s strategy to scale company operations

    Zyme Communications
    www.enhancedgenomics.com
    Healthcare and Life Science, Science and Engineering 09 Jan 2026

    Enhanced Genomics appoints Dr Katerina Leftheris to its Board of Directors

    Experienced leader in preclinical and clinical drug development will support expansion of Company’s therapeutics pipeline for complex and common genetic diseases

    Zyme Communications
    FairJourney Bio
    Healthcare and Life Science 08 Jan 2026

    FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

    PORTO, Portugal, 08 January, 2026 – FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P.

    Zyme Communications
    Dr Steven Bishop, CMO, Qureight and Muhunthan Thillai, MD, Co-founder and CEO, Qureight
    Healthcare and Life Science 07 Jan 2026

    Qureight appoints Dr Steven Bishop as Chief Medical Officer

    Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies

    Zyme Communications
    FUJIFILM Biosciences
    Healthcare and Life Science 05 Jan 2026

    FUJIFILM Irvine Scientific now officially FUJIFILM Biosciences

    Rebrand announced in June as part of Fujifilm Life Sciences Group restructuring becomes official

    Zyme Communications
    CHITOSE and FUJIFILM Biosciences
    Healthcare and Life Science 18 Dec 2025

    CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing

    Collaboration formed to accelerate biopharmaceutical manufacturing combining high performing CHO-MK cells and GMP-manufactured culture media

    Zyme Communications
    Atelerix and Cherry Biotech
    Healthcare and Life Science 15 Dec 2025

    Atelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models

    Partnership brings together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in preclinical research and biotech sectors

    Zyme Communications
    EpilepsyGTx
    10 Dec 2025

    EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

    Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE)Future financings to advance a pipeline of transformativ
    Zyme Communications
    VALANX Biotech
    Healthcare and Life Science 09 Dec 2025

    VALANX Biotech establishes Board of Directors

    Renowned industry leaders, Michael Boehler, Alexander Schwartz, Urs Spitz and Ingo Nagler, appointed to guide strategic and commercial development

    Zyme Communications
    Dr Henry Danahay, Head of Biology, Enterprise Therapeutics
    Healthcare and Life Science 09 Dec 2025

    Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

    ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearanceResults showed excellent consistency between preclinical and clinical behaviour of ETD001Phase 2 trial
    Zyme Communications
    Lab Thread logo
    Healthcare and Life Science 08 Dec 2025

    Lab Thread announces Beta release of Unified Lab Software Platform

    Designed to streamline collaboration across biological research, combining real-time data management, analysis, DNA sequence design, chat and review functions within one intuitive, easy to use systemInterested parties invited to register for beta access via the Lab Thre
    Zyme Communications
    Dr Nicola Thompson, CEO, TRIMTECH Therapeutics and	Ms Alison Lawton, Chair of the Board of Directors, TRIMTECH Therapeutics
    Healthcare and Life Science 02 Dec 2025

    TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board

    Experienced biotech Chair and executive will guide corporate growth and development 

    Zyme Communications
    Alastair Carrington, CEO, Atelerix and Nicola Kingswell,  Scientific Director, Labskin
    Healthcare and Life Science 02 Dec 2025

    Atelerix and Labskin partner to enable long-distance transport of advanced in vitro skin models

    Agreement to broaden access, streamline logistics, and reduce variability associated with temperature-sensitive shipping of 3D tissue models, without cryopreservationJoint webinar to present trial performance data and best-practice workflows for global research communit
    Zyme Communications
    Winners of the OBN Awards 2025
    Healthcare and Life Science 27 Nov 2025

    OBN Awards 2025 celebrate the most exciting innovations and inspiring achievements happening across the Life Sciences industry

    Abingdon, UK, 27 November 2025: – OBN (UK) Ltd, the membership organisation whose mission is to catalyse success in the life science industry, is thrilled to announce the winners of the 17th annual OBN Awards, an evening organised by 

    Zyme Communications
    SPT Labtech’s firefly® liquid handling platform	PacBio’s Kinnex™ full-length RNA kit
    Healthcare and Life Science 20 Nov 2025

    SPT Labtech enables automated PacBio Kinnex full-length RNA-seq library preparation workflow on SPT’s firefly platform

    Automation of Kinnex full-length RNA-seq kit on firefly platform streamlines library preparation for large-scale transcriptomic studiesValidated at Seattle Children’s Genomics & Spatial Biology CoLab, the workflow delivers consistent, high-quality data, supporting t
    Zyme Communications
    ONE BioHub and Scottish Brain Sciences logo
    Healthcare and Life Science 17 Nov 2025

    Scottish Brain Sciences opens new Alzheimer’s clinical research centre at ONE BioHub

    Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s researchONE BioHub provides Scottish Brain Sciences with infrastructure and integrated support to scale operations and drive forward its pioneering neurologic
    Zyme Communications
    Stephen Shuttleworth, Chief Scientific Officer,  Mosaic Therapeutics andThomas Fuchs,  Chief Executive Officer, Mosaic Therapeutics
    Healthcare and Life Science 17 Nov 2025

    Mosaic Therapeutics appoints Dr Stephen Shuttleworth as Chief Scientific Officer

    Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership teamStephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisat

    Pagination

    • First page «
    • Previous page ‹
    • …
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Page 6
    • …
    • Next page ›
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS